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BACKGROUND. Both prostate cancer and diabetesmellitus are common diseases in African-
American men. High insulin levels and insulin resistance have been implicated in prostate
cancer development, which has prompted a recent investigation of a possible role for germline
variation in the insulin gene (INS) and prostate cancer risk.
METHODS. Four hundred sixty-six African-American men with and without prostate cancer
from the FlintMen’sHealth Studywere typed for the INS Pst1 genotype using restriction digest
and direct sequencing. An association between the Pst1 genotype and prostate cancer was
examined using crude and age-adjusted logistic regression models.
RESULTS. African-American men who were homozygous for the INS PstI CC genotype were
1.59 timesmore likely to be diagnosedwith prostate cancer compared tomenwith the TT or TC
genotypes (95% CI¼ 0.93–2.72). The association appeared stronger among diabetics compared
to non-diabetics; however this observation was not statistically significant.
CONCLUSIONS. Our study, taken together with the report of [Ho et al. Br J Cancer 88:263–
269, 2003], suggests that the INS Pst1 CC genotype is associated with prostate cancer risk in
African-American men. Germline variation in the INS gene should be more fully explored in
multiethnic studies to elucidate themolecular variant(s) associatedwith prostate carcinogenesis.
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INTRODUCTION
Prostate cancer is the most common cancer among
American men and is the second leading cause of
cancer deaths in the United States. Age, African-
American race, and family history are well-established
risk factors for this disease [1]. African-American men
have an approximately 1.5-fold higher incidence of
prostate cancer and a nearly 2.5-fold higher incidence
of distant disease compared to Caucasian men [2]. The
likely causes which explain the racial differences in
prostate cancer development and progression have not
been fully elucidated, but likely include genetic,
environment, and sociological factors.
African-American men are also more commonly
diagnosed with type 2 diabetes mellitus compared to
Caucasian men. Using data from the Third National
Health andNutrition Examination Survey (NHANES),
Robbins et al. [3] showed that African-American race is
associated with an approximately 50% increase in the
risk of type 2 diabetes mellitus in men (age-adjusted
OR¼ 1.43, 95%CI¼ 1.03–1.99). In this study, the excess
risk of diabetes could not be explained by other factors
including socioeconomic variables and body size. The
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proposed pathophysiological mechanism for type 2
diabetes is peripheral insulin resistance in combination
with relative insulin deficiency.
Several groups have explored the potential relation-
ship between prostate cancer and various aspects
of insulin physiology. Using data from a case-control
study of prostate cancer conducted in China, Hsing
et al. [4] demonstrated that men in the highest tertile of
insulin resistance had a 2.8-fold increased risk or
prostate cancer (95% CI¼ 1.6–4.7). Other reports have
shown an increased risk of prostate cancer in menwith
high insulin levels [5] as well as a relationship between
serum insulin levels and advanced tumor stage and
risk of prostate cancer recurrence [6,7].
Given the potentially important role of insulin in
prostate cancerdevelopment,Hoet al. [8] testedgenetic
variation in the insulin gene (INS) to determine its
potential association with prostate cancer susceptibil-
ity. Tight linkage disequilibrium has previously been
reported between 10 SNPs spanning a 4.1 kb genomic
segment on chromosome 11p15.5 containing the INS
gene, therefore these investigators elected to test a
single SNP (þ1127 INS Pst1) in the 30 untranslated
region (UTR) of the gene. Using DNA samples from a
hospital-based case-control study,Ho et al. [8] detected
an increased risk of prostate cancer inmenwho had the
homozygous CC INS Pst1 genotype (OR¼ 1.74, 95%
CI¼ 0.99–3.05). The strongest association, however,
was observed in the subset of men who were over age
54 years, either African-American or Caucasian, and
who did not report a personal history of diabetes
(OR¼ 6.33, 95% CI 1.87–21.4).
The Flint Men’s Health Study (FMHS) is a commu-
nity-based case-control study of prostate cancer in
African-American men between the ages of 40–79. To
further explore the potential association between dia-
betes, germline variation in the INS gene and prostate
cancer, we genotyped 466 men with and without
prostate cancer for the þ1127INS Pst1 SNP and herein
describe the association of the CC genotype with
prostate cancer in our study population.
MATERIALSANDMETHODS
Control Subjects
Data collection for the FMHS began in 1996 and
concluded in 2002. Informed consent was obtained
from all study participants, and protocols were
approved by the Institutional Review Board at the
University of Michigan Medical School. As described
previously, disease-free controls were identified from a
probability sample of African-American men in Flint,
Michigan or in selected census tracts in neighboring
Beecher Township (Genesee County, Michigan) [9].
The source population for controls includes all African-
American men aged 40–79 living in Genesee County.
Men in older age groupswere over-sampled to increase
the number of eligible subjects for analyses pertain-
ing to prostate cancer. From the initial sample of
943 men, 732 were willing to participate and deter-
mined to be eligible to complete the detailed in-home
epidemiologic interview, which covered information
on health behaviors such as smoking, drinking and
physical activity; occupational exposures, general
health condition and medical history of chronic ill-
nesses, family history of prostate cancer and demo-
graphic information.
Subjects were then asked to undergo a prostate
cancer screening protocol, which included providing a
blood sample for a serum total prostate-specific antigen
(PSA)measurement, and undergoing a comprehensive
urological examination. A total of 379 men completed
the interview, blood draw and clinical examination.
Men with an abnormal digital rectal examination and/
or elevated total PSA concentration (4.0 ng/ml) were
referred for prostate biopsy. Twenty eight men subse-
quently diagnosed with biopsy-confirmed prostate
cancer were included in the study as cases; the
remaining 351 were included in our control sample.
Case Subjects
Prostate cancer case recruitment from the same
community began in 1999 and was completed in
2002. Cases were identified using the Genesee County
Community-WideHospitalOncologyProgram (CHOP)
registry, which includes the three hospitals for the
county: Hurley Hospital, Genesys Regional Medical
Center, and McLaren Regional Medical Center. Case
participation in the study required (1) an in-home
interview as in the controls; (2) a review of the hospital
and registry records for informationon stage,Gleason’s
grade of differentiation, treatment, and pre-diagnosis
PSAvalue; (3) anthropometricmeasurements; and (4) a
blood sample for DNA and freezer storage of serum
and plasma. An expert in genitourinary pathology at
the University of Michigan reviewed the pathological
material and assigned Gleason grade. One hundred
twenty five African-American men aged 40–79 who
were residents of Genesee County and who had been
diagnosedwithprostate cancer completedall aspects of
the case protocol. The final case group includes the 28
newlydiagnosed cases identifiedduring recruitment of
potential controls.
LaboratoryMethods
Genomic DNA was extracted from whole blood
using a Puregene DNA extraction kit (Gentra Systems,
Inc., Research Triangle Park, NC). Of the 351 control
and 125 case samples, 9 and 1, respectively, were
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removed due to technical reasons. The INS PstI
genotypes were analyzed for 342 controls without the
clinical diagnosis of prostate cancer and 124 cases.
Genotyping of the INS PstIwas performed usingminor
modifications of the restriction fragment length poly-
morphism (RFLP) analysis described by Ho et al. [8].
Primers were designed to amplify a 503 bp region of
the INS gene containing the þ1127 Pst1 SNP. The
forward primer sequence was 50CGGGGGAAGG-
AGGTGGGACAT, while the reverse primer sequence
was 50ACAACAGTGCCGGGAAGTGGGG. PCR pri-
mers were purchased from Invitrogen (Carlsbad, CA).
All genotypes were independently interpreted by a
second researcher, and 18% of genotypes were con-
firmed by repeat restriction digest. Direct sequencing
was used to independently confirm 7% of all samples,
and complete concordance was observed between the
genotypes obtained by sequencing and RFLP analysis.
Statistical Analysis
The distribution of the INS PstI genotype along with
other sociodemographic and clinical characteristics
were examined in the overall study population as well
as by case status. Differences in genotype frequency
between cases and controls were tested using the
Mantel–Haenszel Chi-square test. Unconditional logi-
stic regression was performed to obtain multivariable
odds ratios with associated 95% confidence intervals
for the association between INS PstI genotype and
prostate cancer, adjusting for potentially important
covariates and prostate cancer. The TC and TT geno-
types were combined in the final analysis given the
rarity of the TT genotype. The final models adjusted
simultaneously for INS PstI genotype, age, BMI, and
diabetes. Differences in the associations between INS
PstI genotype and prostate cancer by BMI and diabetes
status were tested using the Breslow–Day test for
homogeneity.
Approximately 50% of FMHS control men were
tested for prostate cancer at multiple time points.
Therefore, to avoid lead time bias in the multivariable
analysis, age was calculated based on the same date for
all cases and controls. This date was the most recent
follow-up date from the entire sample, with the excep-
tion that age at death was used for the 37 controls that
died prior this date. Subjects were considered to have
a positive family history of prostate cancer if they re-
ported that a father, son, and/or brother had ever been
diagnosed with prostate cancer. Subjects were consid-
ered to have diabetes based on the subjects’ self-report
of physician-diagnosed diabetes. BMI was calculated
by dividing weight in kilograms by height in meter
squared, using measurements of weight and height
obtained during the clinical exam and these measures
were then categorized based on the World Health
Organization (WHO) definitions of overweight and
obesity: obese (30), overweight (25BMI< 30), or
normal BMI (<25). The Cochran–Armitage trend test
was calculated to determine if variableswithmore than
two categories had a linear trend of increasing risk of
prostate cancer for each successive category. All anal-
yses were performed using the Statistical Analysis
System (SAS v. 8.2, Cary, NC). Two tailed tests were
used for all comparisons and P-values of less than 0.05
were considered statistically significant.
RESULTS
Overall, the men with prostate cancer that were
genotyped in this report were significantly older
than men without prostate cancer, 64.3 years versus
56.1 years (P< 0.0001). A positive family history for
prostate cancer was reported by 21.8% of cases
compared to 16.7% of controls (P¼ 0.22). Both BMI
and diabetes were positively associated with prostate
cancer; however, these associations were not statisti-
cally significant (Table I).
TABLE I. Distributionof Clinical CharacteristicsbyCase/Control Status andAssociated








Normal (<25) 25.4% 33.3% —
Overweight (25–29.9) 40.2% 36.3% 1.45 (0.87–2.44)
Obese (30) 34.4% 30.4% 1.49 (0.87–2.54)
Diabetes 0.286
Yes 22.6% 17.8% 1.34 (0.81–2.22)
No 77.4% 82.2% —
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The INS PstI genotypes obtained from 466 FMHS
participants exhibited Hardy–Weinberg equilibrium.
The CC genotype was most frequently observed in
both cases and controls, 83.9% and 76.6%, respectively
(Table II). The TT genotype was observed in only three
men or 0.6% of the entire study sample. Our results
suggest that men with the INS PstI CC genotype had a
1.59-fold greater risk of prostate cancer diagnosis as
compared to men with the TT or TC genotype (95%
CI¼ 0.93–2.72). We also pooled the FMHS data with
the genotype data from 96 African-Americanmenwith
prostate cancer and 67disease-free controls reportedby
Ho et al. [8]. The pooled estimate of prostate cancer risk
associated with the INS Pst1 CC genotype was 1.53
(95% CI¼ 1.01–2.32). Among the cases, there was no
significant association between the INS PstI CC geno-
type and prostate cancer grade (comparing Gleason
score6 to Gleason score 7 cases) or age at diagnosis
(data not shown).
No differences were observed in the risk for prostate
cancer associated with the INS PstI CC genotype in
obese compared to non-obese men (Table III). The risk
of prostate cancer associated with the CC genotype
appeared greater among men who reported the
diagnosis of diabetes (OR¼ 2.35, 95% CI¼ 0.76–7.26)
compared to those who did not (OR¼ 1.55, 95%
CI¼ 0.82–2.94), although the difference was not
significant.
DISCUSSION
This is the first independent confirmation of the
association between the INS PstI CC genotype and
prostate cancer as initially described in a multiethnic,
hospital-based case-control study at Albert Einstein
College of Medicine in New York City. Since our study
population was comprised solely of African-American
men, we elected to combine the data from 466 African-
American FMHS participants with the subset of 163
African-American men from the New York City study.
In this combined sample of 629 men, the INS PstI CC
genotype was associated with a 1.53-fold increase risk
of prostate cancer (95% CI¼ 1.01–2.32).
The INS gene, comprised of three exons, is located
between the insulin-like growth factor 2 (IGF2) gene
and the tyrosinehydroxylase (TH) gene in chromosome
11p15. The Pst1 polymorphism is located in the 30 UTR
INS. Given the likely role of the 30 UTR in mRNA
stability, it is possible that this polymorphism is
playing a direct role in altering insulin physiology
which ultimately contributes to prostate carcinogen-
esis. However, tight linkage disequilibrium has also
been observed in the region of the INS gene [10] and so
it is also possible that the Pst1 C allele is linked to the
disease-associated haplotype. In this case, further
investigations must be completed to define the specific
alteration which leads to prostate cancer in men.
Despite the fact that both our study aswell as the Ho
et al. [8] observed similar increases in risk of prostate
cancer associated with the Pst1 INS C allele, there
are some differences in our study designs and results
that should be noted. The cases and controls in the
TABLE II. Distributionof INSPstIGenotypes andOtherCharacteristicsbyCase/Control Status andAssociatedOddsRatios
for Prostate CancerDiagnosisWith 95%Conf|dence Intervals
Data source INS PstI genotype Prostate cancer cases Disease-free controls Odds ratio (95% CI)
FMHS data
CC 104 (83.9%) 262 (76.6%) 1.59 (0.93–2.72)a
TC 19 (15.3%) 78 (22.8%) —
TT 1 (0.8%) 2 (0.6%) —
Ho et al. [8]
African-American men CC 78 (81.3%) 48 (71.6%) 1.72 (0.82–3.59)a
TC 17 (17.7%) 18 (26.9%) —
TT 1 (1.0%) 1 (1.5%) —
Pooled data
CC 182 (82.7%) 310 (76.8%) 1.53 (1.01–2.32)
TC or TT 38 (17.3%) 99 (24.2%) —
aOdds ratio compares CC genotype to TC and TT genotypes combined.
TABLE III. Age-AdjustedOdds Ratios of INSPstICC
Genotypeby BMIandDiabetes Strata
Odds ratio (95% CI) CC versus TC/TT
BMI
Obese (30) 1.67 (0.62–4.51)
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New York City study were identified in a clinic setting
and were matched by birth year, race and country of
origin. The FMHS is a community-based study in
whichcontrolswere identifiedusingprobability sampl-
ing minimizing the potential for selection bias. How-
ever, one possible limitation of our studywas that only
approximately 50% of interviewed subjects ultimately
completed all aspects of the clinical examination for
prostate cancer in the first wave of the study, which
may introduce bias due to non-participation. Heeringa
et al. [11] examined the potential selection bias due to
non-participation that may have occurred in the FMHS
and observed that men who completed all aspects of
the study protocol were younger, more likely to be
experiencing urological symptoms and were more
likely to have a family history or prostate cancer com-
pared to those men who did not undergo clinical
examination. The high rate of prostatectomy among the
FMHS cases (data not shown) suggests that the FMHS
cases may have earlier stage disease compared to the
target population. Because prostate cancer is a late-
onset disease, both our study and that of Ho et al. [8]
may have enrolledmen as controls whowill ultimately
be diagnosed with prostate cancer. However, in case-
control studies, the selection of controls from the same
or similar reference population assumes that these in-
dividuals to some unknown degree may later be diag-
nosed as cases.
The Ho et al. [8] study revealed that the strongest
association between INS genotype and prostate cancer
was in non-diabeticmenwhowere over 55 years of age.
The men who were homozygous CC also were more
likely to be older and have a moderately to well-
differentiated cancer (Gleason score<7). In contrast, no
relationship between INS genotype andprostate cancer
age at diagnosis or Gleason score was detected in the
FMHS, and the OR attributed to the CC genotype was
higher amongdiabetics in the FMHS.As themajority of
FMHS cases presented with earlier stage disease, it is
possible there was not enough variation in our sample
for us to detect an association between INS genotype
and prostate cancer severity. Racial differences is
the prevalence of exposure could account for the dis-
crepancies observed by diabetes status. Larger studies
ofmultiethnic cohorts are necessary to further elucidate
these potential relationships.
In conclusion, members of the insulin gene family
have become intriguing candidates for genetic studies
of prostate cancer susceptibility. Although the relation-
ships between diabetes, insulin levels, insulin resis-
tance, and obesity are complex, molecular studies
performed in the context of carefully designed epide-
miological studies have the opportunity to tease out
potential associations. Our study provides some con-
firmation to the investigation conducted byHo et al. [8]
in that the observed risk associated with the Pst1 INS
CC genotype in African-American men was similar to
the results from their investigation conducted in a
multiethnic population. More thorough studies of
germline variants in this region will uncover the true
causative mutation that may play a role in prostate
carcinogenesis directly or indirectly through insulin
action.
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